Cargando…
Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
[Image: see text] Bicycle toxin conjugates (BTCs) are a promising new class of molecules for targeted delivery of toxin payloads into tumors. Herein we describe the discovery of BT8009, a Nectin-4 targeting BTC currently under clinical evaluation. Nectin-4 is overexpressed in multiple tumor types an...
Autores principales: | Mudd, Gemma E., Scott, Heather, Chen, Liuhong, van Rietschoten, Katerine, Ivanova-Berndt, Gabriela, Dzionek, Katarzyna, Brown, Amy, Watcham, Sophie, White, Lewi, Park, Peter U., Jeffrey, Phil, Rigby, Mike, Beswick, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661471/ https://www.ncbi.nlm.nih.gov/pubmed/36204777 http://dx.doi.org/10.1021/acs.jmedchem.2c00065 |
Ejemplares similares
-
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
por: Rigby, Michael, et al.
Publicado: (2022) -
Spécification technique tiroir unite de generation 8009
Publicado: (1978) -
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2
por: Gaynor, Katherine U., et al.
Publicado: (2023) -
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism
por: Hurov, Kristen, et al.
Publicado: (2021) -
Discovery and
Optimization of a Synthetic Class of
Nectin-4-Targeted CD137 Agonists for Immuno-oncology
por: Upadhyaya, Punit, et al.
Publicado: (2022)